Abstract
MDL 26,024GO was shown to be an orally absorbed mediator release inhibitor in the rat PCA and PPA tests. In addition, the compound was shown to both elicit and inhibit elicitation of the Bezold-Jarisch reflex in the dog. MDL 26,024GO also significantly reduced Ascaris-induced changes in pulmonary mechanics in cynomolgus monkeys. The compound inhibited both early and late phase antigen induced-changes in Ascaris-sensitive sheep, as well as the increased airway hyperreactivity which normally follows antigen challenge. These results suggest the compound may have therapeutic potential in the treatment of asthma.
| Original language | English (US) |
|---|---|
| Pages (from-to) | 431-434 |
| Number of pages | 4 |
| Journal | Agents and Actions |
| Volume | 27 |
| Issue number | 3-4 |
| DOIs | |
| State | Published - Jun 1 1989 |
ASJC Scopus subject areas
- Toxicology
- Pharmacology (medical)
Fingerprint Dive into the research topics of 'Pharmacological profile of MDL 26,024GO: A novel antiasthmatic agent'. Together they form a unique fingerprint.
Cite this
Baugh, L., Abraham, W., Matthews, E., & Lahr, P. (1989). Pharmacological profile of MDL 26,024GO: A novel antiasthmatic agent. Agents and Actions, 27(3-4), 431-434. https://doi.org/10.1007/BF01972843